Deprescribing and Anti-CGRP preventive therapy in medication-overuse headache associated with migraine: pathophysiological rationale and single-center real world evidence.

Medication-overuse headache (MOH) is a common issue for many migraine sufferers. It happens when people take too much medication for migraines, leading to more headaches. This study looked at a new approach to treating MOH. Researchers combined two methods: deprescribing medications and using anti-CGRP therapy. Deprescribing aims to reduce reliance on pain medications. Anti-CGRP therapy targets specific pathways involved in migraine without worsening medication overuse. In this study, 47 patients were monitored. After six months, 85.1% of patients reported at least a 50% reduction in monthly migraine days. After twelve months, 78.7% reported more than a 75% reduction. The findings suggest that this combined method could be effective for many patients with MOH. It highlights the importance of addressing both medication overuse and migraine mechanisms for better outcomes. Clinical relevance: This research indicates that combining deprescribing with anti-CGRP therapy may significantly reduce migraine days for patients with medication-overuse headache.